Jaguar Health, Inc., a commercial stage natural-products pharmaceuticals company, focuses on developing novel, sustainably derived gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Its Mytesi (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Canalevia is the company's lead animal prescription drug product candidate intended for treatment of various forms of diarrhea in dogs; and Equilevia is Jaguar's non-prescription product for total gut health in equine athletes. Canalevia and Equilevia contain ingredients isolated and purified from the Croton lechleri tree, which is sustainably harvested. In addition, the Company's products include Neonorm Calf and Neonorm Foal. Mytesi, Canalevia, Equilevia, and Neonorm are distinct products that act at the same last step in a physiological pathway generally present in mammals. Jaguar Health, Inc. is based in San Francisco, California.